Welcome to our dedicated page for MapLight Therapeutics SEC filings (Ticker: MPLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
MapLight Therapeutics director George Pavlov bought 25,000 shares of Voting Common Stock in open-market transactions. The purchases occurred on February 18, 19, and 20, 2026, at weighted average prices of about $17.48, $17.57, and $17.86 per share, bringing his directly held stake to 25,000 shares.
Robert Malenka submitted a Form 144 through Morgan Stanley Smith Barney LLC reporting proposed sales of Common shares. The filing lists multiple transactions and recent dispositions, including sales on 02/13/2026 for 12,116 shares ($220,685.67) and on 01/29/2026 for 21,262 shares ($394,469.63).
The record also shows restricted stock vesting under a registered plan on 01/23/2026 (quantity 2,195). The filing identifies the broker as Morgan Stanley Smith Barney LLC and lists NASDAQ as the market.
MapLight Therapeutics director Robert C. Malenka reported an open‑market sale of 12,116 shares of Voting Common Stock to cover tax obligations tied to restricted stock unit settlements. The weighted average sale price was $18.21 per share, with individual trades ranging from $18.00 to $18.59.
After this transaction, he held 339,254 shares directly and 31,672 shares indirectly through the Robert C. Malenka Living Trust, where he serves as sole trustee with voting and dispositive power. Shares retained by him remain subject to a 180‑day lock‑up following the October 26, 2025 final prospectus for the company’s initial public offering.
T. Rowe Price Investment Management, Inc. has filed a Schedule 13G reporting beneficial ownership of 2,799,180 shares of MapLight Therapeutics Inc. common stock, representing 6.2% of the outstanding class as of the event date of 12/31/2025.
The firm indicates the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MapLight. It also expressly denies being the beneficial owner of the securities beyond what is reported in the filing.
Forbion Growth Opportunities Fund III Cooperatief U.A. and Forbion Growth III Management B.V. report a 7.1% beneficial ownership stake in MapLight Therapeutics, Inc. voting common stock. They beneficially own 3,226,400 shares with shared voting and dispositive power and no sole power over any shares. This percentage is based on 45,373,033 MapLight common shares outstanding as of November 24, 2025, as cited from the company’s Form 10-Q. Both reporting entities are organized in the Netherlands and file jointly on this Schedule 13G.
A shareholder of MPLT has filed a Rule 144 notice to sell 12,116 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of 220,685.67. The issuer had 45,373,033 shares outstanding when this notice was prepared.
The shares to be sold were acquired on 01/23/2026 through vesting of restricted stock under a registered plan, treated as payment for services rendered. Over the prior three months, the same seller, Robert Malenka, completed several sales of MPLT common stock, including 21,262 shares on 01/29/2026 for gross proceeds of 394,469.63.
MapLight Therapeutics director Timothy John Garnett reported an open‑market purchase of Voting Common Stock on February 10, 2026. Through the Timothy J Garnett Revocable Trust, he bought 14,124 shares at a weighted average price of $17.89 per share, with individual trades between $17.76 and $17.90. Following this transaction, the trust holds 14,124 shares indirectly for him, and he also holds 49,525 shares directly.
MapLight Therapeutics director Robert C. Malenka sold shares of voting common stock mainly to cover taxes tied to equity awards. On February 10, 2026 he sold 6,622 shares at a weighted average price of $18.12, and on February 11, 2026 he sold 241 shares at $18.00.
According to the footnotes, these sales were made to satisfy tax obligations upon settlement of restricted stock units. After the transactions, he directly owned 351,370 shares of voting common stock and indirectly held 31,672 shares through the Robert C. Malenka Living Trust, where he serves as sole trustee with voting and dispositive power.
The remaining securities are still subject to a lock-up agreement related to MapLight Therapeutics’ initial public offering, under which he agreed, with certain exceptions, not to sell or transfer shares for 180 days following the final prospectus dated October 26, 2025.
Robert Malenka filed a Form 144 notice to sell MPLT common stock. The filing covers a planned sale of 241 shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of 4338.00, to be sold on or about 02/11/2026 on NASDAQ.
The 241 shares were acquired on 01/23/2026 as restricted stock vesting under a registered plan, in exchange for services rendered. The notice also lists recent sales of MPLT common stock during the past three months, including 21,262 shares sold on 01/29/2026 for gross proceeds of 394469.63 and 7,039 shares sold on 02/02/2026 for 126835.04.
Robert Malenka has filed a Form 144 notice to sell 6,622 shares of MPLT common stock. The shares were acquired on 01/23/2026 through restricted stock vesting under a registered plan, as payment for services rendered.
The planned sale, with an aggregate market value of $119,962.83, is to be executed through Morgan Stanley Smith Barney LLC on or around 02/10/2026 on the NASDAQ exchange. MPLT had 45,373,033 common shares outstanding at the time listed. Over the prior three months, Malenka reported several MPLT common stock sales totaling tens of thousands of shares and several hundred thousand dollars in gross proceeds.